|
|
Previous Article | Table of Contents | Next Article 
Blood, Vol. 93 No. 6 (March 15), 1999:
pp. 1798-1808
REVIEW ARTICLE
Vitamin K-Dependent Biosynthesis of -Carboxyglutamic Acid
By
Bruce Furie,
Beth A. Bouchard, and
Barbara C. Furie
From the Center for Hemostasis and Thrombosis Research, Division of
Hematology-Oncology, Beth Israel Deaconess Medical Center, and Harvard
Medical School, Boston, MA.
 |
INTRODUCTION |
VITAMIN K, AN ESSENTIAL vitamin, is a
cofactor for a single known enzymatic reaction: the
conversion of glutamic acid to -carboxyglutamic acid in
vitamin K-dependent proteins during their biosynthesis. Since
the discovery of vitamin K and its association with blood
coagulation,1 many milestones have been passed on the road
to understanding the biological role of vitamin K. Important early
landmarks include the discovery of vitamin K antagonists and their
introduction as pharmacologic agents for anticoagulation2; the discovery of -carboxyglutamic acid in blood clotting
proteins3,4; the identification of -carboxyglutamic acid
as a metal binding amino acid that confers metal binding properties on
proteins, a requirement for protein-membrane
interaction5,6; the detection of an enzymatic activity (ie,
the vitamin K-dependent -glutamyl-carboxylase) that
catalyzes the incorporation of CO2 into glutamic
acid5; the identification of an intervening sequence (the
propeptide) between the signal peptide and mature vitamin K-dependent
protein7; and the discovery of the requirement
for8 and the sufficiency of9 the
-carboxylation recognition site within the propeptide in directing
synthesis of -carboxyglutamic acid on the adjacent Gla domain on the
precursor protein. More recent advances include the purification and
cloning of the vitamin K-dependent carboxylase (carboxylase)10,11; the determination of the
three-dimensional structure of the Gla domain of prothrombin and
observation of an internal carboxylate-Ca2+
network12; the proposal of a mechanism of vitamin
K-mediated base enhancement of carboxylase action13; and
the regulation of enzymatic vitamin K epoxidase activity by glutamate
containing substrate.14 Because carboxylase activity is
found in essentially all mammalian tissues15 and because
-carboxyglutamic acid has been observed in both vertebrates and
invertebrates, this amino acid must play an important biological role
in protein function. The biosynthesis of -carboxyglutamic acid is
the topic of this review.
 |
-CARBOXYGLUTAMIC ACID: CHEMISTRY OF BIOSYNTHESIS |
The requirement for vitamin K as an enzyme cofactor is unique to the
vitamin K-dependent carboxylase and the biosynthesis of
-carboxyglutamic acid. In this reaction, the -proton on glutamic acid is abstracted, followed by the addition of CO2; the
intermediate in this reaction is a -glutamyl carbanion16
(Fig 1). The mechanism by which vitamin K
participates as a cofactor with the -carboxylase remains a puzzle.
The most attractive hypothesis is that an active oxygenated species of
vitamin K abstracts a hydrogen from the -carbon of glutamic acid,
with subsequent collapse of the activated vitamin K species to vitamin
K epoxide. Carbon dioxide is subsequently added to the -carbon of
glutamic acid. Based on a nonenzymatic model,13 a "base
strength amplification mechanism" has been proposed to explain the
conversion of vitamin KH2 into an oxygenated intermediate
of sufficient basicity to abstract a hydrogen from the -carbon of a
glutamic acid.17 The proposed intracellular intermediate is
short-lived. "Footprints" of the formation of such an unstable
intermediate by the mechanism proposed have been discovered by the
identification of a stable, isotopically labeled degradation product of
vitamin K dioxide during enzymatic vitamin K-dependent carboxylation in
vitro.18,19

View larger version (14K):
[in this window]
[in a new window]
| Fig 1.
Biosynthetic pathway for vitamin K-dependent production
of -carboxyglutamic acid. It has been hypothesized that a free
cysteine residue in the carboxylase converts vitamin KH2
into a "strong base" of sufficient basicity to abstract a
hydrogen from the -carbon of glutamic acid.17
Subsequently, CO2 is added to the -carbon of glutamic
acid to form -carboxyglutamic acid. The activated vitamin K species
collapses into vitamin K epoxide and is recycled back to vitamin
KH2, following the action of two vitamin K reductases, one
of which is sensitive to warfarin.25
|
|
Thus, the vitamin K-dependent carboxylase is also a vitamin K
epoxidase, and, under normal conditions, for each molecule of -carboxyglutamic acid generated, a molecule of vitamin K epoxide is
generated. The coupling of -carboxyglutamic acid and vitamin K
epoxide production was first noted with partially purified
carboxylase20 and has been confirmed with purified
carboxylase.21 In addition to its role as a recognition
sequence,8,9 binding of the propeptide of a vitamin
K-dependent protein substrate to the carboxylase stimulates
-glutamyl carboxylation.22 Because oxidation of reduced
vitamin K precedes reaction at the -C-H on the substrate glutamate
residue and -carboxylation cannot occur without formation of vitamin
K epoxide, this observation suggests that vitamin K epoxidation by the
carboxylase may be stimulated by propeptide. Kinetic studies have
determined that the propeptide increase in carboxylase catalytic
efficiency is in selective lowering of an energy barrier preceding the
-glutamyl carbanion intermediate either by accelerating formation of
the reactive vitamin K intermediate or proton abstraction from a
substrate glutamyl residue.23
The short-lived highly reactive vitamin K intermediate is potentially
toxic, and it would be undesirable for it to be generated intracellularly in the absence of substrate glutamate residues. Indeed,
it has been recently demonstrated that the carboxylase has no epoxidase
activity until the enzyme system is activated.14 Glutamate-containing substrates bound to the vitamin K-dependent carboxylase convert its vitamin K epoxidase function from an inactive to an active state. Therefore, epoxidase activity is turned-off, and no
highly reactive vitamin K intermediate is generated, unless a
carboxylase substrate is bound to the enzyme.14
One intriguing question regarding the mechanism of the vitamin
K-dependent carboxylase is whether the enzyme is processive or
distributive. If processive, then once a vitamin K-dependent protein
substrate has bound the enzyme all target Glu residues are converted to
Gla residues before the protein substrate dissociates from the enzyme.
If distributive, the protein substrate associates with and dissociates
from the carboxylase multiple times before carboxylation is complete. A
second interesting question is whether there is a preferred order of
carboxylation of the target Glu residues in a vitamin K-dependent
protein substrate. Morris et al24 have
reported that, when purified carboxylase carboxylates a peptide analog
of the propeptide and Gla domain of factor IX, the products of the
reaction are skewed toward highly carboxylated forms. These
investigators suggest that only two mechanisms can support these
results: either the carboxylase is processive or it is distributive
with the requirement that partially carboxylated forms of the factor IX
peptide analog are more efficiently carboxylated than the
uncarboxylated peptide. Although the currently available data suggest
that the carboxylase is processive, conclusive experiments remain to be
performed. No information is currently available regarding the order of
carboxylation of Glu residues within a vitamin K-dependent protein substrate.
 |
RECYCLING OF THE CARBOXYLASE COFACTOR VITAMIN K |
In its naturally occurring state, vitamin K is at the quinone oxidation
state and must be reduced to the hydroquinone form, the active cofactor
for the vitamin K-dependent carboxylase. The enzyme responsible for
this conversion is known as the vitamin K epoxide reductase, so named
because it also reduces the vitamin K epoxide formed during the
carboxylation reaction.25 The vitamin K epoxide reductase
works at low concentrations of vitamin K epoxide and vitamin K quinone
and is likely the physiologically important enzyme for recycling
vitamin K.26 This is the enzyme that is inhibited by
warfarin, resulting in insufficient vitamin K hydroquinone to support
full carboxylation of the vitamin K-dependent proteins of blood
coagulation, thus its role as a pharmacologically useful anticoagulant.
It is believed that the enzymatic activity of the vitamin K epoxide
reductase resides in a membrane-bound, multiprotein enzyme complex in
the endoplasmic reticulum. Recently, two components of this complex
have been identified: microsomal epoxide hydrolase27 and a
member of the glutathione S-transferase super gene
family.28
A second enzyme, DT-diapharase, an NAD(P)H dehydrogenase, reduces the
quinone form of vitamin K but not vitamin K epoxide.25 Furthermore, this enzyme requires high concentrations of vitamin K26 and likely does not play a role in vitamin K recycling
at physiologic tissue concentrations of vitamin K. This enzyme may play
an important role when vitamin K, in the quinone form, is used to
overcome warfarin intoxication.
 |
HOW ARE PROTEINS SELECTED FOR -CARBOXYLATION? ROLE OF THE
PROPEPTIDE AND THE -CARBOXYLATION RECOGNITION SEQUENCE |
The propeptides of the vitamin K-dependent proteins contain a
-carboxylation recognition site that is required for -glutamyl carboxylation.8 In one known example, matrix Gla protein,
the -carboxylation recognition site resides within the mature
protein sequence.29 The amino acids of the
-carboxylation recognition site bind directly to the vitamin
K-dependent carboxylase.30 Although no obvious consensus
sequence prevails in the carboxylation recognition sites of vitamin
K-dependent proteins (Fig 2),
this site is best defined by a Z-F-Z-X-X-X-X-A motif, where Z is an aliphatic hydrophobic residue (Ile, Val, Leu), F is phenylalanine, A is
alanine, and X is any amino acid. Recent studies have emphasized that
phenylalanine at residue 16 is preferred in carboxylase substrates, but leucine, valine, and lysine at this position also support carboxylation.31 Indeed, gas6, a recently described Gla-domain containing protein,32 has a leucine at residue
16 and is carboxylated.33

View larger version (53K):
[in this window]
[in a new window]
| Fig 2.
The -carboxylation recognition sites of known vitamin
K-dependent proteins. The propeptides of the vitamin K-dependent blood
coagulation proteins contain a -carboxylation recognition site that
directs carboxylation.8 A phenylalanine at position 16
and an alanine at position 10 are well conserved within the
propeptides of carboxylase substrates, as are aliphatic hydrophobic
residues (isoleucine, leucine, and valine) at position 17 and 15.
Recent data suggest that, whereas phenylalanine at 16 is preferred,
leucine, valine, and lysine at this position can also support
carboxylation.31
|
|
Disruption of this carboxylation recognition site in factor IX yields a
mature factor IX protein that either lacks or is deficient in
-carboxyglutamic acid.8 Thus, this site is required for -carboxylation. It is most likely that this region of the blood coagulation protein precursor docks with the membrane-bound
carboxylase, bringing the active site of the carboxylase in close
proximity to the substrate glutamate residues on the precursor form of
the vitamin K-dependent proteins. There is no evidence that the amino acid sequence or three-dimensional structural elements in the immediate
vicinity of the glutamate residues contribute significantly to the
recognition of the protein substrate by the carboxylase. Indeed, a
double point mutant of prothrombin, in which serine substituted for
cysteines 17 and 22 disrupted a conserved disulfide loop, was fully
carboxylated when expressed in CHO cells.9 In addition, a
prothrombin propeptide/thrombin chimera was constructed by deleting the
Gla, aromatic amino acid stack, and kringle domains of prothrombin.
This construct has the signal peptide and -carboxylation recognition
site-containing propeptide juxtaposed to a glutamate-rich C-terminal
region of prothrombin. Seven or eight of the eight glutamic acids
within the first 40 residues of the NH2-terminus adjacent
to the propeptide underwent complete carboxylation when this protein
was expressed in CHO cells.9 These results indicate that
the prothrombin -carboxylation recognition site on the propeptide is
sufficient to direct carboxylation of adjacent glutamic acid residues
in the propeptide/thrombin chimera by the vitamin K-dependent carboxylase without regard for the sequence context of the glutamic acid substrate or structures defined by disulfide bonds. Thus, we
hypothesize that any protein will undergo -carboxylation if it meets
the following criteria: (1) the protein includes a -carboxylation recognition site that interacts with the -glutamyl carboxylase; (2)
the protein is trafficked through the rough endoplasmic reticulum during protein biosynthesis; (3) the cell has the carboxylase enzyme
associated with the rough endoplasmic reticulum; (4) there are glutamic
acid residues within 40 residues of the -carboxylation recognition
site; and (5) intracellular vitamin K is present.
Others have proposed that a second recognition site might reside within
the mature sequence of the nascent vitamin K-dependent protein.29 A Gla domain consensus sequence,
E16XXXE20XC22, common to the
vitamin K-dependent blood and bone proteins, was disrupted by
site-specific mutagenesis.34 This was associated with the
expression of incompletely carboxylated recombinant protein C in a
mammalian expression system. Furthermore, recombinant protein C in
which glutamic acid residues in the Gla domain were systematically mutated to aspartic acid residues was incompletely
carboxylated.35 These results were interpreted to suggest
that this consensus sequence is important for carboxylation. In
contrast, we prepared 10 mutants of prothrombin in which each of the
glutamic acid residues in the Gla domain were modified to aspartic
acid.36 Expression of these mutant prothrombins generated
fully carboxylated protein. These results most likely relate to
differences in the heterologous mammalian expression systems used or
efficiency of carboxylation of individual vitamin K-dependent proteins
and not to a specific role for glutamic acid in ligand binding energy.
Naturally occurring propeptide mutants of factor IX have been described
in humans. The mutation of alanine 10 to threonine is associated
with marked sensitivity of patients to warfarin anticoagulation and
severe inhibition of carboxylation, well in excess of that observed
with the other vitamin K-dependent proteins.37 Similarly, mutation of alanine 10 to either threonine or to
valine is associated with marked sensitivity of patients to
phenprocoumon.38 In all cases, the phenotype and factor IX
levels of patients with these mutations at alanine 10 were
normal, unless they were exposed to a vitamin K antagonist. Alanine
10 has been shown to be a part of the carboxylation recognition
site by mutational analysis and using small peptide substrates for
carboxylation. Mutation is associated with diminished -carboxylation
both during expression of recombinant protein in CHO
cells8,39 and during in vitro37 -carboxylation. However, there is no evidence of defective
carboxylation of factor IX in men with these mutations
when they are not challenged with warfarin. This paradoxical effect has
not been adequately explained to date. With a reduced affinity for the
carboxylase, the mutant profactor IX may be at a kinetic disadvantage
when the concentration of the other carboxylase substrate, reduced vitamin K, is limited by inhibition of the recycling enzymes and other
vitamin K-dependent proteins can compete for enzyme (Fig 1).
 |
VITAMIN K-DEPENDENT CARBOXYLASE: THE ENZYMATIC MACHINERY FOR THE
SYNTHESIS OF -CARBOXYGLUTAMIC ACID |
Vitamin K-dependent carboxylase activity was first demonstrated in
liver in 1975, shortly after the discovery of -carboxyglutamic acid.5 Because the enzyme is membrane-associated and
unstable, purification of the enzyme was difficult and refractory to
standard techniques. However, considerable insight about this enzyme
system was gained from the analysis of solubilized and partially
purified carboxylase.25 With the discovery that the
propeptide of the vitamin K-dependent proteins directs
-carboxylation,8 the use of the propeptide for affinity
chromatography led first to significant purification30 and
finally to the isolation of the carboxylase.10 Molecular
cloning of the human and bovine vitamin K-dependent
carboxylase11,40 predicted a single chain protein of 758 amino acids. The protein, with a molecular weight of about 94,000, is
dominated by hydrophobic amino acids, particularly toward the
N-terminal third of the molecule, but the presence of transmembrane
spanning regions is uncertain. The human carboxylase gene is localized
on chromosome 2 at 2p12.41 The gene is 13 kb in length and
contains 15 exons.42 In humans in the tissues examined, two
transcripts were observed. In rats, the gene is 16.3 kb in length, with
similar intron/exon boundaries as in the human gene. Only one
transcript was observed in the rat.43
The predicted sequences of human, bovine, and rat carboxylase have been
reported, and these share a high degree of homology: 88% between human
and rat carboxylase and 94% between human and bovine
carboxylase.43 The carboxylase has minimal sequence
homology with other proteins, with the closest being NADH-ubiquinone
oxidoreductase chain 2, cytochrome C, and soybean lipoxygenase. Price
and Williamson44 observed that carboxylase shares homology
over 24 residues (495-518) with the region of matrix Gla protein that
bears the -carboxylation recognition site. These investigators
suggested that this sequence might play a regulatory role, blocking the
active site of the enzyme and preventing nonspecific protein
carboxylation. The propeptide of a vitamin K-dependent protein could
displace this internal -carboxylation recognition site to gain
access to the enzyme active site. Berkner and Pudota45 have
recently reported that the carboxylase can itself be carboxylated, with
3 moles of Gla per mole of enzyme. It appears that this modification
can occur in the absence of an exogenous peptide containing a
-carboxylation recognition site, suggesting that the regulatory
model proposed by Price and Williamson44 does not apply to
carboxylation of the carboxylase. The functional significance of this
modification of the carboxylase is currently unknown.
Although the protein sequence of the carboxylase is known, the general
organization of functional regions of the protein is appreciated only
at low resolution. The known functional properties of this enzyme
include a carboxylase active site, an epoxidase active site, a
propeptide binding site that docks substrate, a propeptide binding site
that stimulates carboxylase and epoxidase activity, and a vitamin K
binding site. Using substrate- and propeptide-based affinity labeling
reagents, the vitamin K-dependent carboxylase active site and
propeptide binding site were located, at least in part, within the
hydrophobic N-terminal third of the protein between residues 1 and
225.46-49 A preliminary study based on the yeast two-hybrid
system concludes that the propeptide binds to the N-terminal third of
the enzyme.50 However, one recent report suggests that the
propeptide binding site on the carboxylase is located on the more
hydrophilic C-terminal two thirds of the enzyme between residues 438 and 758.51 Another study reports that the active site of
the enzyme is located in a central region of the carboxylase between
residues 350 and 508, with both an N-terminal and C-terminal tryptic
peptide labeled with a propeptide-substrate based affinity
label.52 Several sets of mutagenesis experiments bear on
this question as well. Point mutations at the charged residues 234/235,
406/408, and 513/515 result in carboxylase species with reduced
affinity for propeptide.49 Truncations of bovine carboxylase from the C-terminus at amino acids 712 or 676 result in
carboxylase species that bind to propeptide and glutamate containing substrates equivalently to the wild-type enzyme, suggesting that the
extreme C-terminal region is not involved in propeptide
binding.53 It is not clear what experimental variations
have led to various affinity-labeling experiments giving differing
results. The data given above, taken in toto, suggest that the
propeptide and perhaps the glutamate binding site of the carboxylase
include regions in the N-terminal third and central third of the
enzyme. Alternatively, there may be more than one propeptide binding
site.22 Without a structural model on which to base
functional studies, it is not presently possible to reconcile these results.
 |
INTRACELLULAR SITE OF -CARBOXYLATION DURING PROTEIN SYNTHESIS |
Subcellular fractionation methods have previously demonstrated that
carboxylase activity resides in both the endoplasmic
reticulum54 and the Golgi apparatus.55 Studies
of the glycoforms of prothrombin56 and protein
C57 during biosynthesis have indicated that core
glycosylation but not formation of complex carbohydrate proceeds
carboxylation. These data suggest that carboxylation is complete in the
endoplasmic reticulum. In both cases, removal of the propeptide occurs
late in the processing pathway. We have used antibodies to directly localize carboxylase and the various processed forms of prothrombin during biosynthesis. Using anticarboxylase antibodies, we have confirmed the intracellular localization of the carboxylase in both the
endoplasmic reticulum and the Golgi. The intracellular sites of
carboxylation and subsequent propeptide cleavage along the pathway of
prothrombin biosynthesis were monitored for recombinant prothrombin
synthesis in Chinese hamster ovary cells expressing prothrombin.58 Antibodies specific to processing
intermediates (uncarboxylated prothrombin or uncarboxylated
proprothrombin, carboxylated proprothrombin, or carboxylated
prothrombin) were used for immunocytolocalization. These
studies showed that uncarboxylated proprothrombin undergoes
-carboxylation to carboxylated proprothrombin in the endoplasmic
reticulum. The carboxylated proprothrombin leaves the endoplasmic
reticulum intact and is further processed in the Golgi apparatus to
remove the propeptide. Furin has been implicated in the cleavage of the
propeptide from factor IX.59 However, there is a large
family of related proconvertases that are involved in cleavage of
propeptides that contain Arg or Lys at the 2 position and Arg at
1.60 The actual proconvertase that removes the
propeptides of the vitamin K-dependent proteins is not known. Although
carboxylase is detected in the Golgi complex by immunostaining,
carboxylation appears to be complete in the endoplasmic reticulum. The
carboxylase as a membrane-bound protein may be carried to the Golgi by
bulk flow and may get recycled to the endoplasmic reticulum
(Fig 3).

View larger version (34K):
[in this window]
[in a new window]
| Fig 3.
Pathway for synthesis of vitamin K-dependent proteins.
Vitamin K-dependent proteins are synthesized in the endoplasmic
reticulum as precursor proteins containing a signal peptide and a
-carboxylation recognition site usually found within a propeptide of
the proprotein. After cleavage of the signal peptide, the proprotein
binds to the endoplasmic reticulum membrane-associated vitamin
K-dependent carboxylase via its -carboxylation recognition site.
Recent data suggest that binding of a glutamic acid-containing
substrate to the carboxylase converts it from an inactive to an active
state.14 The carboxylase catalyzes the conversion of
glutamic acid residues to -carboxyglutamic acid residues. As is
indicated by an arrow with a question mark connecting two active
carboxylase molecules, it is unclear whether carboxylation of
proproteins occurs by a processive mechanism. The carboxylated
proprotein is trafficked through the cell to the trans Golgi network,
where the propeptide is cleaved by an unknown proconvertase. The
inactive form of the carboxylase may be carried to the Golgi and then
recycled back to the ER. The fully modified, mature protein is then
secreted from the cell.
|
|
Prothrombin and the other -carboxylated extracellular vitamin
K-dependent proteins bind to acidic membranes in the presence of
calcium ions. The question arises as to what prevents the fully -carboxylated precursor vitamin K-dependent proteins, such as proprothrombin, from binding to endoplasmic reticular membranes during
transit through the biosynthetic pathway and getting "hung up?"
The calcium concentration in the endoplasmic reticulum is high, in
contrast to the cytoplasm, and is sufficient to support protein-membrane interaction. It is known that chemical modification of
the N-terminus of prothrombin inhibits membrane binding.61 Similarly, fully carboxylated profactor IX does not bind to membranes in the presence of calcium ions, whereas factor IX does.59
It would appear that the propeptide attached to factor IX prevents proper folding of the Gla domain, the expression of the phospholipid binding site, and the interaction of profactor IX with membranes.
 |
THE FUNCTION OF -CARBOXYGLUTAMIC ACID |
Why is -carboxyglutamic acid so broadly used in biology? The answers
are not in yet, but knowledge of the function of -carboxyglutamic acid is expanding. -Carboxyglutamic acid has been extensively studied in three protein families. These include the vitamin
K-dependent blood coagulation (factor IX, factor VII, factor X, and
prothrombin) and regulatory (protein C and protein S) proteins,
proteins of mineralized tissue (bone Gla protein, matrix Gla protein),
and neurotoxins in the venom of cone snails. There is high likelihood that many other vitamin K-dependent proteins exist outside of these
three families. Several proteins that contain Gla domains homologous to
the Gla domains of blood coagulation but of unknown function have
recently been identified. These include Gas6 and two proline-rich
-carboxyglutamic acid-containing proteins
(Table 1).
An extensive review of the literature supporting our current knowledge
of the role of -carboxyglutamic acid is beyond the scope of this
review. A brief discussion is included to provide the reader with an
indication of the consequences of this posttranslational modification.
-Carboxyglutamic acid distinguishes itself from aspartic acid and
glutamic acid by containing two carboxyl groups in its side chain. The
bivalent nature of -carboxyglutamic acid is similar to Igs or
fibrinogen, for example. In these cases, a structural framework is
formed via the linking of one ligand to another through a common
bivalent, symmetrical molecule. As is described below, such is the case
for the formation of the calcium-carboxylate network that stabilizes
the Gla domains and, in the vitamin K-dependent proteins of blood
coagulation, allows expression of the phospholipid binding site
(Fig 4).

View larger version (15K):
[in this window]
[in a new window]
| Fig 4.
The calcium-carboxylate networks of the factor IX
Gla-domain and conantokin G. One role of -carboxyglutamic acid is to
stabilize a protein structure by formation of an extended
calcium-carboxylate network. This property of -carboxyglutamic acid
is used to stabilize the factor IX Gla-domain and conantokin G. (A) The
calcium ligands for the Gla-domain of factor IX determined by NMR and
molecular dynamics simulation64,65 are shown. In addition
to the -carboxyglutamic acid residues, Tyr 1 and Ser 3 provide
ligands to calcium 5 and Asn 2 provides a ligand to calcium 3. Tyr 1, Ser 3, and Asn 2 are shown in light grey. Calcium ions 3 through 5 are
buried within the protein and not exposed to water. (B) The calcium
ligands for conantokin G determined by NMR and molecular dynamics
simulation78 are shown. Each calcium ion is coordinated by
three or four carboxylate oxygens contributed by two
-carboxyglutamic acid residues. The -carboxyglutamic acid
residues and the bound calcium ions are solvent exposed.
|
|
The Plasma Proteins of Blood Coagulation
The vitamin K-dependent blood coagulation and regulatory proteins
contain 10 to 12 -carboxyglutamic acid residues in the Gla domain,
located within the first 40 residues of the N-terminus of the mature
proteins. The Gla domain in association with the adjacent aromatic
amino acid stack domain functions as a membrane binding component of
these proteins. -Carboxyglutamic acid is a metal binding amino acid
that confers metal binding properties on the vitamin K-dependent
proteins. With the addition of calcium ions, these proteins undergo a
structural transition that leads to the exposure of a phospholipid
binding site. In most cases in which it has been investigated, neither
aspartic acid nor glutamic acid will substitute for the function of
-carboxyglutamic acid, emphasizing the importance of both carboxyl
groups. The inability of glutamic acid to substitute for
-carboxyglutamic acid is perhaps best illustrated by the usefulness
of the anticoagulant drug sodium warfarin. As described above and shown
in Fig 1, sodium warfarin prevents the recycling of vitamin K from the
oxidized to the reduced form, leading to decreased -glutamyl
carboxylation due to insufficient active cofactor. The abnormal forms
of the vitamin K-dependent proteins are undercarboxylated, having
glutamic acid residues at some or all of the positions that are usually
carboxylated, and are for the most part biologically inert. Systematic
mutation of individual carboxylatable glutamic acid residues in
recombinant prothrombin36 or protein C35,62,63
has yielded molecules with modest to severe functional defects, again
indicating the importance of the bifunctional -carboxyglutamic acid
side chain.
Prothrombin.
The X-ray crystal structure of prothrombin fragment 1 first showed that
the Gla domain is highly structured, and many of the -carboxyglutamic acid residues in this domain coordinate internal calcium ions that are not exposed to solvent.12 Most of the -carboxyglutamic acid side chains point inward to a linear array of
internal calcium ions. Several of these calcium ions are completely sequestered inside the core of the Gla domain, ie, not exposed to solvent.
Factor IX.
The factor IX Gla domain, studied by 2D NMR spectroscopy in a peptide
consisting of the Gla-aromatic amino acid stack domain, is
characterized by a similar fold of the polypeptide
backbone.64 The location of the calcium binding sites in
the internal core structure is nearly identical in prothrombin and
factor IX.65
Factor VII.
The crystal structure of the factor VII-tissue factor complex showed
the structure of the Gla domain of factor VII in the presence of
calcium ions.66 Its structure is nearly identical to its
homolog in prothrombin.
The phospholipid membrane binding site of the vitamin K-dependent
proteins is expressed on the surface of the Gla domain. X-ray structure
showed the curious exposure of three hydrophobic residues on the
protein surface, suggesting a potential role for these residues in
membrane interaction.12 Site-specific mutagenesis of
homologous residues in protein C interfered with the membrane binding
properties of this protein, but mutation of other hydrophobic residues
did not perturb membrane binding significantly.67
Sunnerhagen et al68 compared the
NMR-determined solution structure of the calcium-free Gla-EGF domain
pair from factor X with a model of the calcium-bound factor X Gla
domain based on presumed structural homology with prothrombin and
concluded that calcium-induced exposure of hydrophobic amino acids in
the Gla domain is critical for membrane binding. Direct comparison of
the NMR determined structures of the calcium-stabilized form of factor
IX, which binds to membranes, and the magnesium-stabilized form of
factor IX, which does not bind to membranes, implicated the N-terminal
11 amino acid residues that form a loop in the Gla
domain.69 Based on correlation of membrane binding
properties of the vitamin K-dependent proteins of plasma with homology
considerations, McDonald et al70 has recently
proposed an alternative membrane contact site that implicates residues
11, 33, and 34 in this process.
Gla-Containing Proteins of Mineralized Tissue
Whereas the role of -carboxyglutamic acid is well defined in the
plasma proteins, this role remains uncertain in proteins/peptides outside of this family. There have been no successful studies to date
on the structure of -carboxyglutamic acid-containing bone proteins,
including osteocalcin (bone Gla protein) and matrix Gla protein.
Although these proteins bind to calcium ions, the specific structural
role of -carboxyglutamic acid has not yet been defined. Osteocalcin
function remains uncertain. However, increased bone formation,
including higher bone mass and bones of improved functional quality,
were observed in osteocalcin-deficient mice.71 Spontaneous
and ultimately fatal calcification of arteries and cartilage was
observed in mice lacking matrix Gla protein,72 suggesting
that one of its functions is to control and limit extraosseous calcification.
Other Mammalian Vitamin K-Dependent Proteins
Gas6 is a vitamin K-dependent protein with marked sequence homology in
the Gla domain to the vitamin K-dependent blood coagulation and
regulatory proteins and in particular with protein S.32 Gas6 is released from and potentiates the growth of vascular smooth muscle cells. Gas6 is a calcium-dependent ligand for the receptor tyrosine kinases Axl and Sky/Rse.73,74 The domain structure includes a Gla domain, loop domain, EGF domain, and two tandem "globular" (or G) domains. This protein contains
-carboxyglutamic acid, and Gas6 synthesized in the presence of
warfarin and thus lacking -carboxyglutamic acid demonstrates no
thrombin-inducible growth potentiating activity or receptor binding
ability.33 In contrast, Gas6 lacking the entire Gla domain
is a functional growth factor, indicating that the tandem G domains are
sufficient to activate Rse phosphorylation.75 This suggests
that the Gla domain may be a negative regulator of the structure of a
growth factor domain located elsewhere on the molecule.
PRGP1 and PRGP2, two proteins named for their
Proline-Rich Gla Protein
characteristic, were identified by searching an expressed sequence tag
database with a protein query sequence based on a consensus sequence
derived from the analysis of the Gla domain of the vitamin K-dependent
blood clotting and regulatory proteins.76 PRGP1, with a
predicted molecular mass of 23 kD, is composed of 198 amino acids after
cleavage of the putative propeptide. PRPG2, with a predicted molecular
mass of 17 kD, has 153 amino acids after the cleavage of the putative
signal peptide and propeptide. Both proteins are characterized by Gla
domains preceded by prototypic propeptides, a transmembrane domain and
a cytoplasmic domain rich in proline and containing the motifs PPXY and
PXXP. These proteins are expressed in a variety of extrahepatic
tissues, in contrast to the blood clotting proteins. The function of
these newly discovered proteins is unknown.
As discussed above, the carboxylase itself has sequence homology with
the region of matrix Gla protein containing the -carboxylation recognition site.44 Under some conditions, the carboxylase
has been reported to be carboxylated,45 although the role
of -carboxyglutamic acid in the enzyme remains to be determined.
Conantokins
Despite an extensive search for -carboxyglutamic acid across most
phyla, the distribution of this amino acid had been thought to be
limited to vertebrates until a conotoxin from the venomous cone snail
was isolated and sequenced.77 Conotoxins are small, paralyzing neuroactive peptides that are injected into prey after a
cone snail harpoons its victim. Conantokin G, the sleeper peptide, is
17 residues long and contains five -carboxyglutamic acid residues. In the conantokin G:Ca2+ complex, the Gla side chains are
oriented externally, and Gla 3, Gla 7, Gla 10, and Gla 14 are aligned
in a linear array.78 This structural motif is clearly
distinct from that of the vitamin K-dependent blood coagulation
proteins. However, a carboxylate:Ca2+ network is also
present. A similar structure and carboxylate:metal ion network has been
described in the conantokin G:Mg2+ complex.79 A
related conotoxin, conantokin T, has a similar helical structure in the
presence of magnesium ions80 and calcium ions.81 A propeptide that serves a similar role as those of vertebrate vitamin K-dependent proteins in identifying them as substrates for the -carboxylase has recently been discovered for
conantokin G.82 The propeptide sequence does not contain the -CRS of vertebrate vitamin K-dependent proteins, and the -CRS
within the conantokin G propeptide has not been identified. A large
number of neuroactive Gla-containing conotoxins have recently been identified.
 |
SUMMARY |
The sole known biological role of vitamin K is as a cofactor for the
vitamin K-dependent -glutamyl carboxylase in the synthesis of
-carboxyglutamic acid. This enzyme has been purified to homogeneity and both its cDNA sequence and gene structure determined. The mechanism
of action of vitamin K in the reaction catalyzed by this enzyme remains hypothetical.
Protein precursors destined to undergo posttranslational
-carboxylation contain a -carboxylation recognition site, often within the propeptide of a precursor protein, that binds to the -carboxylase. This recognition element assures conversion of glutamic acid to -carboxyglutamic acid on carboxylase substrates. -Carboxyglutamic acid is a calcium-binding amino acid and is required for the function of vitamin K-dependent proteins. The blood
clotting and regulatory proteins require -carboxyglutamic acid for
Ca2+-induced interaction with membrane surfaces.
A common feature of vitamin K-dependent proteins is the formation of a
network of protein carboxylate ligands bound to Ca2+. This
network, first described in prothrombin, is defined by -carboxyglutamic acid and is associated with the stabilization of a
unique conformer and the exposure of solvent-accessible hydrophobic amino acids that are available for membrane or protein interaction.
 |
ACKNOWLEDGMENT |
The authors thank members of this laboratory, past and present, who
have contributed so much to the development of our understanding of
-carboxyglutamic acid synthesis and function.
 |
FOOTNOTES |
Submitted June 9, 1998; accepted October 26, 1998.
The work performed in this laboratory was supported by grants from the
National Institutes of Health (Grants No. HL18834, HL38216, and
HL42443). B.A.B. was supported by a Judith Graham Pool Postgraduate
Research Fellowship from the National Hemophilia Foundation.
Address reprint requests to Bruce Furie, MD, BIDMC Cancer Center, KS
158, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston,
MA 02215.
 |
REFERENCES |
1.
Dam H:
The antihemorrhagic vitamin of the chick. Occurrence and chemical nature.
Nature
135:652, 1935
2.
Campbell HA, Link KP:
Studies on the hemorrhagic sweet clover disease IV. The isolation and crystallization of the hemorrhagic agent.
J Biol Chem
138:21, 1941[Free Full Text]
3.
Stenflo J, Fernlund P, Egan W, Roespstorff P:
Vitamin K dependent modifications of glutamic acid residues in prothrombin.
Proc Natl Acad Sci USA
71:2730, 1974[Abstract/Free Full Text]
4.
Nelsestuen GL, Zytkovicz TH, Howard JB:
The mode of action of vitamin K. Identification of -carboxyglutamic acid as a component of prothrombin.
J Biol Chem
249:6347, 1974[Abstract/Free Full Text]
5.
Esmon CT, Sadowski JA, Suttie JW:
A new carboxylation reaction. The vitamin K-dependent incorporation of H14CO3 into prothrombin.
J Biol Chem
250:4744, 1975[Abstract/Free Full Text]
6.
Sperling R, Furie BC, Blumenstein M, Keyt B, Furie B:
Metal binding properties of -carboxyglutamic acid.
J Biol Chem
253:3898, 1978[Free Full Text]
7.
Kurachi K, Davie EW:
Isolation and characterization of cDNA coding for human factor IX.
Proc Natl Acad Sci USA
79:6461, 1982[Abstract/Free Full Text]
8.
Jorgensen M, Cantor A, Furie BC, Shoemaker C, Furie B:
Recognition site directing vitamin K-dependent -carboxylation resides on the propeptide of factor IX.
Cell
48:185, 1987[Medline]
[Order article via Infotrieve]
9.
Furie BC, Ratcliffe J, Tward J, Jorgensen MJ, Blaszkowsky L, DiMichele D, Furie B:
The -carboxylation recognition site is sufficient to direct vitamin K-dependent carboxylation on an adjacent glutamate-rich region of thrombin in a propeptide-thrombin chimera.
J Biol Chem
272:28258, 1997[Abstract/Free Full Text]
10.
Wu S-M, Morris DP, Stafford DW:
Identification and purification to near homogeneity of the vitamin K-dependent carboxylase.
Proc Natl Acad Sci USA
88:2236, 1991[Abstract/Free Full Text]
11.
Wu S-M, Cheung W-F, Frazier DF, Stafford DW:
Cloning and expression of the cDNA for human -glutamyl carboxylase.
Science
254:1634, 1991[Abstract/Free Full Text]
12.
Soriano-Garcia M, Padmanabhan K, de Vos AM, Tulinsky A:
The Ca2+ ion and membrane binding structure of the Gla domain of Ca-prothrombin fragment 1.
Biochemistry
31:2554, 1992[Medline]
[Order article via Infotrieve]
13.
Ham SW, Dowd P:
On the mechanism of action of vitamin K. A new nonenzymic model.
J Am Chem Soc
112:1660, 1990
14.
Sugiura I, Furie B, Walsh C, Furie BC:
Propeptide and glutamate-containing substrates bound to the vitamin K-dependent carboxylase convert the vitamin K epoxidase from an inactive to an active state.
Proc Natl Acad Sci USA
94:9069, 1997[Abstract/Free Full Text]
15.
Vermeer C, De Boer-Van den Berg MA:
Vitamin K-dependent carboxylase.
Haematologia (Budap)
18:71, 1985[Medline]
[Order article via Infotrieve]
16.
Friedman PA, Shia MA, Gallop PM, Griep AE:
Vitamin K-dependent gamma-carbon-hydrogen bond cleavage and nonmandatory concurrent carboxylation of peptide-bound glutamic acid residues.
Proc Natl Acad Sci USA
76:3126, 1979[Abstract/Free Full Text]
17.
Dowd P, Hershline R, Ham SW, Naganathan S:
Vitamin K and energy transduction: A base strength amplification mechanism.
Science
269:1684, 1995[Abstract/Free Full Text]
18.
Dowd P, Ham SW, Hershline R:
Role of oxygen in the vitamin K-dependent carboxylation reaction: Incorporation of a second atom of 18O from molecular oxygen-18O2 into vitamin K oxide during carboxylase activity.
J Am Chem Soc
114:7613, 1992
19.
Kuliopulos A, Hubbard BR, Lam Z, Koski IJ, Furie B, Furie BC, Walsh CT:
Dioxygen transfer during vitamin K-dependent carboxylase catalysis.
Biochemistry
31:7722, 1992[Medline]
[Order article via Infotrieve]
20.
Wood GM, Suttie JW:
Vitamin K dependent carboxylase. Stoichiometry of vitamin K epoxide formation, -carboxyglutamyl formation and -glutamy-3H cleavage.
J Biol Chem
263:3234, 1988[Abstract/Free Full Text]
21.
Morris DP, Soute BAM, Vermeer C, Stafford DW:
Characterization of the purified vitamin K-dependent -glutamyl carboxylase.
J Biol Chem
268:8735, 1993[Abstract/Free Full Text]
22.
Knobloch JE, Suttie JW:
Vitamin K-dependent carboxylase. Control of enzyme activity by the "propeptide" region of factor X.
J Biol Chem
262:15334, 1987[Abstract/Free Full Text]
23.
Li S, Furie BC, Furie B, Walsh CT:
The propeptide of the vitamin K-dependent carboxylase substrate accelerates formation of the -glutamyl carbanion intermediate.
Biochemistry
36:6384, 1997[Medline]
[Order article via Infotrieve]
24.
Morris DP, Stevens RD, Wright DJ, Stafford DW:
Processive post-translational modification: Vitamin K-dependent carboxylation of a peptide substrate.
J Biol Chem
270:30491, 1995[Abstract/Free Full Text]
25.
Suttie JW:
Vitamin K-dependent carboxylase.
Annu Rev Biochem
54:459, 1985[Medline]
[Order article via Infotrieve]
26.
Wallin R, Martin LF:
Warfarin poisoning and vitamin K antagonism in rat and human liver. Design of a system that mimics the system in vivo.
Biochem J
241:389, 1987[Medline]
[Order article via Infotrieve]
27.
Guenther TM, Cai D, Wallin R:
Co-purification of microsomal epoxide hydrolase with the warfarin-sensitive vitamin KI oxide reductase of the vitamin K cycle.
Biochem Pharmacol
55:169, 1998[Medline]
[Order article via Infotrieve]
28.
Cain D, Hutson SM, Wallin R:
Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane.
J Biol Chem
272:29068, 1997[Abstract/Free Full Text]
29.
Price PA, Fraser JD, Metz-Virca G:
Molecular cloning of matrix Gla protein: Implications for substrate recognition by the vitamin K-dependent -carboxylase.
Proc Natl Acad Sci USA
84:8335, 1987[Abstract/Free Full Text]
30.
Hubbard BR, Ulrich MMW, Jacobs M, Vermeer C, Walsh C, Furie B, Furie BC:
Vitamin K-dependent carboxylase: Affinity purification from bovine liver using a synthetic propeptide containing the -carboxylation recognition site.
Proc Natl Acad Sci USA
86:6893, 1989[Abstract/Free Full Text]
31.
Tward JD, Furie BC, Bouchard BA, Jacobs M, Furie B:
Other amino acids than phenylalanine at position 16 in the carboxylation recognition site in the prothrombin propeptide can support -carboxylation.
Blood
90:291a, 1997 (abstr, suppl 1)
32.
Manfioletti G, Brancolini C, Avanzi G, Schneider C:
The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade.
Mol Cell Biochem
13:4976, 1993
33.
Nankano T, Kawamoto K, Kishino J, Nomura K, Higashino K-L, Arita H:
Requirement of -carboxyglutamic acid residues for the biological activity of Gas6: Contribution of endogenous Gas6 to the proliferation of vascular smooth muscle cells.
Biochem J
323:387, 1997
34.
Zhang L, Castellino FJ:
Role of the hexapeptide disulfide loop present in the -carboxyglutamic acid domain of human protein C in its activation properties and in the in vitro anticoagulant activity of activated protein C.
Biochemistry
30:6696, 1991[Medline]
[Order article via Infotrieve]
35.
Zhang L, Jhingan A, Castellino FJ:
Role of individual -carboxyglutamic acid residues of activated human protein C in defining its in vitro anticoagulant activity.
Blood
80:942, 1993[Abstract/Free Full Text]
36.
Ratcliffe J, Furie B, Furie BC:
The importance of specific -carboxyglutamic acid residues in prothrombin: Evaluation by site-specific mutagenesis.
J Biol Chem
268:24339, 1993[Abstract/Free Full Text]
37.
Chu K, Wu SM, Stanley T, Stafford DW, High KA:
A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism.
J Clin Invest
98:1619, 1996[Medline]
[Order article via Infotrieve]
38.
Oldenburg J, Quenzel E-M, Harbrecht U, Fregin A, Kress W, Muller CR, Hertfelder H-J, Schwaab R, Brackmann HH, Hanfland P:
Missense mutations at Ala 10 in the factor IX propeptide: An insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy.
Br J Haematol
98:240, 1997[Medline]
[Order article via Infotrieve]
39.
Huber P, Schmitz T, Griffin J, Jacobs M, Walsh C, Furie B, Furie BC:
Identification of amino acids in the -carboxylation recognition site on the propeptide of prothrombin.
J Biol Chem
265:12467, 1990[Abstract/Free Full Text]
40.
Rehemtulla A, Roth DA, Wasley LC, Kuliopulos A, Walsh CT, Furie B, Furie BC, Kaufman RJ:
In vitro and in vivo functional characterization of bovine vitamin K-dependent -carboxylase expressed in Chinese hamster ovary cells.
Proc Natl Acad Sci USA
90:4611, 1993[Abstract/Free Full Text]
41.
Kuo WL, Stafford DW, Cruces J, Gray J, Solera J:
Chromosomal localization of the gamma-glutamyl carboxylase gene at 2p12.
Genomics
25:746, 1994
42.
Wu S-M, Stafford DW, Frazier LD, Fu Y-Y, High KA, Chu K, Sanchez-Vega B, Solera J:
Genomic sequence and transcription start site for the human -glutamyl carboxylase.
Blood
89:4058, 1997[Abstract/Free Full Text]
43.
Romero EE, Deo R, Velazquez-Estades LJ, Roth DA:
Cloning, structural organization, and transcriptional regulation of the rat vitamin K-dependent -glutamyl carboxylase gene.
Biochem Biophys Res Commun
248:783, 1998[Medline]
[Order article via Infotrieve]
44.
Price PA, Williamson MK:
Substrate recognition by the vitamin K-dependent gamma-glutamyl carboxylase: Identification of a sequence homology between the carboxylase and the carboxylase recogntion site in the substrate.
Prot Sci
2:1987, 1993[Medline]
[Order article via Infotrieve]
45.
Berkner KL, Pudota BN:
Vitamin K-dependent carboxylation of the carboxylase.
Proc Natl Acad Sci USA
95:466, 1998[Abstract/Free Full Text]
46.
Kuliopulos A, Cieurzo CE, Furie B, Furie BC, Walsh CT:
N-Bromoacetyl-peptide affinity labeling of vitamin K dependent carboxylase.
Biochemistry
31:9436, 1992[Medline]
[Order article via Infotrieve]
47.
Kuliopulos A, Nelson NP, Yamada M, Walsh CT, Furie B, Furie BC, Roth DA:
Localization of the affinity peptide-substrate inactivator site on recombinant vitamin K-dependent carboxylase.
J Biol Chem
269:21364, 1994[Abstract/Free Full Text]
48.
Yamada M, Kuliopulos A, Nelson NP, Roth DA, Furie B, Furie BC, Walsh CT:
Factor IX propeptide inactivator: Photoaffinity labeling and localization on the vitamin K-dependent carboxylase.
Biochemistry
34:481, 1995[Medline]
[Order article via Infotrieve]
49.
Sugiura I, Furie B, Walsh CT, Furie BC:
Profactor IX propeptide and glutamate substrate binding sites on the vitamin K-dependent carboxylase identified by site-directed mutagenesis.
J Biol Chem
271:17837, 1996[Abstract/Free Full Text]
50. Brown MA, MacGillivary TA: Analysis of the propeptide
recognition site of human gamma-glutamyl carboxylase by use of the
yeast two-hybrid system. Thromb Haemost 639, 1997 (suppl)
51.
Wu S-M, Mutucumarana VP, Geromanos S, Stafford DW:
The propeptide binding site of the bovine -glutamyl carboxylase.
J Biol Chem
272:11718, 1997[Abstract/Free Full Text]
52.
Maillet M, Morris D, Gaudry M, Marquet A:
The active site region of the vitamin K-dependent carboxylase includes both the amino-terminal hydrophobic and carboxy-terminal hydrophilic domains of the protein.
FEBS Lett
413:1, 1997[Medline]
[Order article via Infotrieve]
53.
Roth DA, Whirl ML, Velazquez-Estades LJ, Walsh CT, Furie B, Furie BC:
Mutagenesis of vitamin K-dependent carboxylase demonstrates a carboxyl terminus-mediated interaction with vitamin K hydroquinone.
J Biol Chem
270:5305, 1995[Abstract/Free Full Text]
54.
Carlisle TL, Suttie JW:
Vitamin K dependent carboxyslase: Subcellular localization of the carboxylase and enzymes involved in vitamin K metabolism in rat liver.
Biochemistry
19:1161, 1980[Medline]
[Order article via Infotrieve]
55.
Wallin R, Stanton C, Hutson SM:
Intracellular maturation of the gamma-carboxyglutamic acid (Gla) region in prothrombin coincides with the release of the propeptide.
Biochem J
291:723, 1993
56.
Swanson JC, Suttie JW:
Prothrombin biosynthesis: Characterization of processing events in rat liver microsomes.
Biochemistry
24:3890, 1985[Medline]
[Order article via Infotrieve]
57.
McClure DB, Walls JD, Grinnell BW:
Post-translational processing events in the secretion pathway of human protein C, a complex vitamin K-dependent antithrombotic factor.
J Biol Chem
267:19710, 1992[Abstract/Free Full Text]
58.
Bristol JA, Ratcliffe JV, Roth DA, Jacobs MA, Furie BC, Furie B:
Biosynthesis of prothrombin: Intracellular localization of the vitamin K-dependent carboxylase and the sites of -carboxylation.
Blood
88:2585, 1996[Abstract/Free Full Text]
59.
Wasley LC, Rehemtulla A, Bristol JA, Kaufman RJ:
PACE/furin can process the vitamin K-dependent profactor IX precursor with the secretory pathway.
J Biol Chem
268:8458, 1993[Abstract/Free Full Text]
60.
Bristol JA, Furie BC, Furie B:
Propeptide processing during factor IX biosynthesis: Effect of point mutations adjacent to the propeptide cleavage site.
J Biol Chem
268:7577, 1993[Abstract/Free Full Text]
61.
Welsch DJ, Nelsestuen GL:
Amino-terminal alanine functions in a calcium-specific process essential for membrane binding by prothrombin fragment 1.
Biochemistry
27:16094, 1988
62.
Zhang L, Castellino FJ:
The contributions of individual gamma-carboxyglutamic acid residues in the calcium-dependent binding of recombinant human protein C to acidic phospholipid vesicles.
J Biol Chem
268:12040, 1993[Abstract/Free Full Text]
63.
Jhingan A, Zhang L, Christiansen WT, Castellino FJ:
The activities of recombinant gamma-carboxyglutamic acid-deficient mutants of activated human protein C toward human coagulation factor Va and factor VIII in purified systems and in plasma.
Biochemistry
33:1869, 1994[Medline]
[Order article via Infotrieve]
64.
Freedman SJ, Furie BC, Furie B, Baleja J:
Structure of the factor IX Gla domain bound to calcium ions.
Biochemistry
34:12126, 1995[Medline]
[Order article via Infotrieve]
65.
Li L, Darden TA, Freedman SJ, Furie BC, Furie B, Baleja JD, Smith H, Hiskey RG, Pedersen LG:
Refinement of the NMR solution structure of the -carboxyglutamic acid domain of coagulation factor IX using molecular dynamics simulation with initial Ca2+ positions determined by a genetic algorithm.
Biochemistry
36:2132, 1997[Medline]
[Order article via Infotrieve]
66.
Banner DW, D'Arcy A, Chene C, Winkler FK, Guha A, Konigsberg WH, Nemerson Y, Kirchofer D:
The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor.
Nature
380:41, 1995
67.
Christiansen WT, Jalbert LR, Robertson RM, Jhingian A, Porok M, Castellino FJ:
Hydrophobic amino acid residues of human anticoagulation protein C that contribute to its functional binding to phospholipid vesicles.
Biochemistry
34:10376, 1995[Medline]
[Order article via Infotrieve]
68.
Sunnerhagen M, Forsen S, Hoffren AM, Drakenberg T, Teleman O, Stenflo J:
Structure of the Ca2+-free GLA domain sheds light on membrane binding of blood coagulation proteins.
Nat Struct Biol
2:504, 1995[Medline]
[Order article via Infotrieve]
69.
Freedman SJ, Blostein MD, Baleja JD, Jacobs M, Furie BC, Furie B:
Identification of the phospholipid binding site in the vitamin K-dependent protein factor IX.
J Biol Chem
271:16227, 1996[Abstract/Free Full Text]
70.
McDonald JF, Shah AM, Schwalbe RA, Kisiel W, Dahlback B, Nelsestuen GL:
Comparison of naturally occurring vitamin K-dependent proteins: Correlation of amino acid sequences and membrane binding properties suggests a membrane contact site.
Biochemistry
36:5120, 1997[Medline]
[Order article via Infotrieve]
71.
Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, Smith E, Bonadio J, Goldstein S, Gundberg C, Bradley A, Karsenty G:
Increased bone formation in osteocalcin-deficient mice.
Nature
382:448, 1996[Medline]
[Order article via Infotrieve]
72.
Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G:
Spontaneous calcification of arteries and cartilage in mice lacking matrix Gla protein.
Nature
385:78, 1997[Medline]
[Order article via Infotrieve]
73.
Ohashi K, Nagata K, Toshima J, Nakano T, Arita H, Tsuda H, Suzuki K, Mizuno K:
Stimulation of the Sky receptor tyrosine kinase by the product of growth arrest-specific gene 6.
J Biol Chem
270:22681, 1995[Abstract/Free Full Text]
74.
Varnum BC, Young C, Elliott G, Garcia A, Baratley TD, Fridell Y-W, Hunt RW, Trail G, Clogston C, Toso RJ, Yanagihara D, Bennett L, Sylber M, Merewether LA, Tseng A, Escobar E, Liu ET, Yamane HK:
Axl receptor tyrosine kinase is stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6.
Nature
373:623, 1995[Medline]
[Order article via Infotrieve]
75.
Mark MR, Chen J, Hammonds RG, Sadick M, Godowski PJ:
Characterization of Gas6, a member of the superfamily of G domain-containing proteins, as a ligand for Rse and Axl.
J Biol Chem
271:9785, 1996[Abstract/Free Full Text]
76.
Kulman JD, Harris JE, Haldeman BA, Davie EW:
Primary structure and tissue distribution of two novel proline-rich -carboxyglutamic acid proteins.
Proc Natl Acad Sci USA
94:9058, 1997[Abstract/Free Full Text]
77.
McIntosh JM, Olivera BM, Cruz LJ, Gray WR:
-Carboxyglutamic acid in a neuroactive toxin.
J Biol Chem
259:14343, 1984[Abstract/Free Full Text]
78.
Rigby A, Baleja J, Li L, Pedersen LG, Furie BC, Furie B:
The role of -carboxyglutamic acid in the calcium-induced structural transition of conantokin G, a conotoxin from the marine cone snail Conus geographus.
Biochemistry
36:15677, 1997[Medline]
[Order article via Infotrieve]
79.
Chen Z, Blandl T, Prorok M, Warder SE, Li L, Zhu Y, Pedersen LG, Ni F, Castellino FJ:
Conformational changes in conantokin-G induced upon binding of calcium and magnesium as revealed by NMR structural analysis.
J Biol Chem
273:16248, 1998[Abstract/Free Full Text]
80.
Skjaerbaek N, Nielsen KJ, Lewis RJ, Alewood P, Craik DJ:
Determination of the solution structures of conantokin-G and conantokin-T by CD and NMR spectroscopy.
J Biol Chem
272:2291, 1997[Abstract/Free Full Text]
81.
Warder SE, Prorok M, Chen Z, Li L, Zhu Y, Pedersen LG, Ni F, Castellino FJ:
The roles of individual gamma-carboxyglutamic acid residues in the solution structure and cation-dependent properties of conantokin-T.
J Biol Chem
273:7512, 1998[Abstract/Free Full Text]
82.
Bandyopadhyay PK, Colledge CJ, Walker CS, Zhou L-M, Hillyard DR, Olivera BM:
Conantokin-G precursor and its role in -carboxylation by a vitamin K-dependent carboxylase from a Conus snail.
J Biol Chem
273:5447, 1998[Abstract/Free Full Text]

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. Schwarz, P. N. Seibel, S. Rahmann, C. Schoen, M. Huenerberg, C. Muller-Reible, T. Dandekar, R. Karchin, J. Schultz, and T. Muller
Detecting species-site dependencies in large multiple sequence alignments
Nucleic Acids Res.,
October 1, 2009;
37(18):
5959 - 5968.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Souri, H. Iwata, W. G. Zhang, and A. Ichinose
Unique secretion mode of human protein Z: its Gla domain is responsible for inefficient, vitamin K-dependent and warfarin-sensitive secretion
Blood,
April 16, 2009;
113(16):
3857 - 3864.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Nimptsch, S. Rohrmann, A. Nieters, and J. Linseisen
Serum Undercarboxylated Osteocalcin as Biomarker of Vitamin K Intake and Risk of Prostate Cancer: A Nested Case-Control Study in the Heidelberg Cohort of the European Prospective Investigation into Cancer and Nutrition
Cancer Epidemiol. Biomarkers Prev.,
January 1, 2009;
18(1):
49 - 56.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Yoshida, P. F. Jacques, J. B. Meigs, E. Saltzman, M. K. Shea, C. Gundberg, B. Dawson-Hughes, G. Dallal, and S. L. Booth
Effect of Vitamin K Supplementation on Insulin Resistance in Older Men and Women
Diabetes Care,
November 1, 2008;
31(11):
2092 - 2096.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Danziger
Vitamin K-dependent Proteins, Warfarin, and Vascular Calcification
Clin. J. Am. Soc. Nephrol.,
September 1, 2008;
3(5):
1504 - 1510.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. L. Coutu, J. H. Wu, A. Monette, G.-E. Rivard, M. D. Blostein, and J. Galipeau
Periostin, a Member of a Novel Family of Vitamin K-dependent Proteins, Is Expressed by Mesenchymal Stromal Cells
J. Biol. Chem.,
June 27, 2008;
283(26):
17991 - 18001.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. K. Azharuddin, D. St. J. O'Reilly, A. Gray, and D. Talwar
HPLC Method for Plasma Vitamin K1: Effect of Plasma Triglyceride and Acute-Phase Response on Circulating Concentrations
Clin. Chem.,
September 1, 2007;
53(9):
1706 - 1713.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Zhu, H. Sun, R. M. Raymond Jr, B. C. Furie, B. Furie, M. Bronstein, R. J. Kaufman, R. Westrick, and D. Ginsburg
Fatal hemorrhage in mice lacking {gamma}-glutamyl carboxylase
Blood,
June 15, 2007;
109(12):
5270 - 5275.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Ozaki, H. Zhang, T. Mizuta, Y. Ide, Y. Eguchi, T. Yasutake, T. Sakamaki, R. G. Pestell, and K. Yamamoto
Menatetrenone, a Vitamin K2 Analogue, Inhibits Hepatocellular Carcinoma Cell Growth by Suppressing Cyclin D1 Expression through Inhibition of Nuclear Factor {kappa}B Activation
Clin. Cancer Res.,
April 1, 2007;
13(7):
2236 - 2245.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Koizume, M.-S. Jin, E. Miyagi, F. Hirahara, Y. Nakamura, J.-H. Piao, A. Asai, A. Yoshida, E. Tsuchiya, W. Ruf, et al.
Activation of Cancer Cell Migration and Invasion by Ectopic Synthesis of Coagulation Factor VII
Cancer Res.,
October 1, 2006;
66(19):
9453 - 9460.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Darghouth, K. W. Hallgren, R. L. Shtofman, A. Mrad, Y. Gharbi, A. Maherzi, R. Kastally, S. LeRicousse, K. L. Berkner, and J.-P. Rosa
Compound heterozygosity of novel missense mutations in the gamma-glutamyl-carboxylase gene causes hereditary combined vitamin K-dependent coagulation factor deficiency
Blood,
September 15, 2006;
108(6):
1925 - 1931.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Johnson, B. A. Soute, C. S. Olver, and D. C. Baker
Defective {gamma}-Glutamyl Carboxylase Activity and Bleeding in Rambouillet Sheep.
Vet. Pathol.,
September 1, 2006;
43(5):
726 - 732.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Johnson, W. S. Laegreid, R. J. Basaraba, and D. C. Baker
Truncated gamma-glutamyl carboxylase in rambouillet sheep.
Vet. Pathol.,
July 1, 2006;
43(4):
430 - 437.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Adams and J. Pepping
Vitamin K in the treatment and prevention of osteoporosis and arterial calcification
Am. J. Health Syst. Pharm.,
August 1, 2005;
62(15):
1574 - 1581.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-K. Tie, C. Nicchitta, G. von Heijne, and D. W. Stafford
Membrane Topology Mapping of Vitamin K Epoxide Reductase by in Vitro Translation/Cotranslocation
J. Biol. Chem.,
April 22, 2005;
280(16):
16410 - 16416.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Schuettrumpf, R. W. Herzog, A. Schlachterman, A. Kaufhold, D. W. Stafford, and V. R. Arruda
Factor IX variants improve gene therapy efficacy for hemophilia B
Blood,
March 15, 2005;
105(6):
2316 - 2323.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Bern
Observations on Possible Effects of Daily Vitamin K Replacement, Especially Upon Warfarin Therapy
JPEN J Parenter Enteral Nutr,
November 1, 2004;
28(6):
388 - 398.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. J. Schurgers, M. J. Shearer, K. Hamulyak, E. Stocklin, and C. Vermeer
Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects
Blood,
November 1, 2004;
104(9):
2682 - 2689.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. L. Booth, K. E. Broe, J. W. Peterson, D. M. Cheng, B. Dawson-Hughes, C. M. Gundberg, L. A. Cupples, P. W. F. Wilson, and D. P. Kiel
Associations between Vitamin K Biochemical Measures and Bone Mineral Density in Men and Women
J. Clin. Endocrinol. Metab.,
October 1, 2004;
89(10):
4904 - 4909.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Rishavy, B. N. Pudota, K. W. Hallgren, W. Qian, A. V. Yakubenko, J.-H. Song, K. W. Runge, and K. L. Berkner
A new model for vitamin K-dependent carboxylation: The catalytic base that deprotonates vitamin K hydroquinone is not Cys but an activated amine
PNAS,
September 21, 2004;
101(38):
13732 - 13737.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Hansson, X. Ma, L. Eliasson, E. Czerwiec, B. Furie, B. C. Furie, P. Rorsman, and J. Stenflo
The First {gamma}-Carboxyglutamic Acid-containing Contryphan: A SELECTIVE L-TYPE CALCIUM ION CHANNEL BLOCKER ISOLATED FROM THE VENOM OF CONUS MARMOREUS
J. Biol. Chem.,
July 30, 2004;
279(31):
32453 - 32463.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. L Booth, I. Golly, J. M Sacheck, R. Roubenoff, G. E Dallal, K. Hamada, and J. B Blumberg
Effect of vitamin E supplementation on vitamin K status in adults with normal coagulation status
Am. J. Clinical Nutrition,
July 1, 2004;
80(1):
143 - 148.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Buil, J. M. Soria, J. C. Souto, L. Almasy, M. Lathrop, J. Blangero, and J. Fontcuberta
Protein C Levels Are Regulated by a Quantitative Trait Locus on Chromosome 16: Results from the Genetic Analysis of Idiopathic Thrombophilia (GAIT) Project
Arterioscler Thromb Vasc Biol,
July 1, 2004;
24(7):
1321 - 1325.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Rezende, R. E. Simmonds, and D. A. Lane
Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex
Blood,
February 15, 2004;
103(4):
1192 - 1201.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. W. Davie
A Brief Historical Review of the Waterfall/Cascade of Blood Coagulation
J. Biol. Chem.,
December 19, 2003;
278(51):
50819 - 50832.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-K. Tie, V. P. Mutucumarana, D. L. Straight, K. L. Carrick, R. M. Pope, and D. W. Stafford
Determination of Disulfide Bond Assignment of Human Vitamin K-dependent {gamma}-Glutamyl Carboxylase by Matrix-assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry
J. Biol. Chem.,
November 14, 2003;
278(46):
45468 - 45475.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. D. Blostein, B. C. Furie, I. Rajotte, and B. Furie
The Gla Domain of Factor IXa Binds to Factor VIIIa in the Tenase Complex
J. Biol. Chem.,
August 15, 2003;
278(33):
31297 - 31302.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. L. Booth, L. Martini, J. W. Peterson, E. Saltzman, G. E. Dallal, and R. J. Wood
Dietary Phylloquinone Depletion and Repletion in Older Women
J. Nutr.,
August 1, 2003;
133(8):
2565 - 2569.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Li, J. C. Lin, H. Wang, J. W. Peterson, B. C. Furie, B. Furie, S. L. Booth, J. J. Volpe, and P. A. Rosenberg
Novel Role of Vitamin K in Preventing Oxidative Injury to Developing Oligodendrocytes and Neurons
J. Neurosci.,
July 2, 2003;
23(13):
5816 - 5826.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. C Binkley, D. C Krueger, T. N Kawahara, J. A Engelke, R. J Chappell, and J. W Suttie
A high phylloquinone intake is required to achieve maximal osteocalcin {gamma}-carboxylation
Am. J. Clinical Nutrition,
November 1, 2002;
76(5):
1055 - 1060.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Rezende, D. A. Lane, B. Mille-Baker, M. M. Samama, J. Conard, and R. E. Simmonds
Protein S Gla-domain mutations causing impaired Ca2+-induced phospholipid binding and severe functional protein S deficiency
Blood,
September 26, 2002;
100(8):
2812 - 2819.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. E. M. Persson, B. O. Villoutreix, A.-M. Thamlitz, K. E. Knobe, and J. Stenflo
The N-terminal Epidermal Growth Factor-like Domain of Coagulation Factor IX. PROBING ITS FUNCTIONS IN THE ACTIVATION OF FACTOR IX AND FACTOR X WITH A MONOCLONAL ANTIBODY
J. Biol. Chem.,
September 13, 2002;
277(38):
35616 - 35624.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P.-J. Lin, D.-Y. Jin, J.-K. Tie, S. R. Presnell, D. L. Straight, and D. W. Stafford
The Putative Vitamin K-dependent gamma -Glutamyl Carboxylase Internal Propeptide Appears to Be the Propeptide Binding Site
J. Biol. Chem.,
August 2, 2002;
277(32):
28584 - 28591.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Roth, C. M. Kessler, K. J. Pasi, B. Rup, S. G. Courter, and K. L. Tubridy
Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates
Blood,
December 15, 2001;
98(13):
3600 - 3606.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. N. Pudota, E. L. Hommema, K. W. Hallgren, B. A. McNally, S. Lee, and K. L. Berkner
Identification of Sequences within the gamma -Carboxylase That Represent a Novel Contact Site with Vitamin K-dependent Proteins and That Are Required for Activity
J. Biol. Chem.,
December 7, 2001;
276(50):
46878 - 46886.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Yu, S. B. White, Q. Zhao, and F. S. Lee
HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation
PNAS,
August 14, 2001;
98(17):
9630 - 9635.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Mizuno, Z. Fujimoto, H. Atoda, and T. Morita
Crystal structure of an anticoagulant protein in complex with the Gla domain of factor X
PNAS,
June 7, 2001;
(2001)
131179698.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. Venter, M. D. Adams, E. W. Myers, P. W. Li, R. J. Mural, G. G. Sutton, H. O. Smith, M. Yandell, C. A. Evans, R. A. Holt, et al.
The Sequence of the Human Genome
Science,
February 16, 2001;
291(5507):
1304 - 1351.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
B. N. Pudota, M. Miyagi, K. W. Hallgren, K. A. West, J. W. Crabb, K. S. Misono, and K. L. Berkner
Identification of the vitamin K-dependent carboxylase active site: Cys-99 and Cys-450 are required for both epoxidation and carboxylation
PNAS,
November 21, 2000;
97(24):
13033 - 13038.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. L. Berkner
The Vitamin K-Dependent Carboxylase
J. Nutr.,
August 1, 2000;
130(8):
1877 - 1880.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
M. A. Brown, L. M. Stenberg, U. Persson, and J. Stenflo
Identification and Purification of Vitamin K-dependent Proteins and Peptides with Monoclonal Antibodies Specific for gamma -Carboxyglutamyl (Gla) Residues
J. Biol. Chem.,
June 23, 2000;
275(26):
19795 - 19802.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. S. Begley, B. C. Furie, E. Czerwiec, K. L. Taylor, G. L. Furie, L. Bronstein, J. Stenflo, and B. Furie
A Conserved Motif within the Vitamin K-dependent Carboxylase Gene Is Widely Distributed across Animal Phyla
J. Biol. Chem.,
November 10, 2000;
275(46):
36245 - 36249.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Mizuno, Z. Fujimoto, H. Atoda, and T. Morita
Crystal structure of an anticoagulant protein in complex with the Gla domain of factor X
PNAS,
June 19, 2001;
98(13):
7230 - 7234.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|